Effect of fremanezumab on quality of life and productivity in patients with chronic migraine.

Neurology · 2020 · PMC7605497 · PMID 32747522

Europe PMC DOI

hedged sentence

0.5918

closest p · 11.8× alpha

0.5918

boldest claim

The sentences

a nonsignificant trendp = 0.5918not close (p > 0.1)

There were no significant differences in absenteeism for either treatment group compared with placebo, despite a nonsignificant trend in the monthly fremanezumab administration group (quarterly: −0.1%, p = 0.5918; monthly: −2.1%, p = 0.0873; placebo: 0.8%).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.